Neon drop · Free ship $75+ · Enter the grid
Login Register
Signal · Product Feed
Olcegepant - CAS# 204697-65-4 Catalog No.:M10814-10 Smiles: CC1CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]2C=1CC[C@@]2(C)O
Olcegepant - CAS# 204697-65-4 Catalog No.:M10814-10 Smiles: CC1CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]2C=1CC[C@@]2(C)O
Olcegepant - CAS# 204697-65-4 Catalog No.:M10814-10 Smiles: CC1CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]2C=1CC[C@@]2(C)O
Olcegepant - CAS# 204697-65-4 Catalog No.:M10814-10 Smiles: CC1CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]2C=1CC[C@@]2(C)O

Olcegepant - CAS# 204697-65-4 Catalog No.:M10814-10 Smiles: CC1CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]2C=1CC[C@@]2(C)O

SKU: 15721875804

4.4
USD120.00 USD149.00

Pay in 4 interest-free payments of $30.00 Learn more

Shipping Estimate
USA
  • USA
  • CAN

Ships within 48 hours · Estimated delivery Aug 7 - Aug 12

Live Spec

Olcegepant - CAS# 204697-65-4 Catalog No.:M10814-10 Smiles: CC1CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]2C=1CC[C@@]2(C)OOlcegepant, also known as BIBN 4096 or BIBN 4096BS is is the first potent and selective non peptide antagonist of the calcitonin gene related peptide 1 (CGRP1) receptor, a key modulator in neurogenic inflammatory pain. In preclinical studies, olcegepant attenuated arterial dilation induced by CGRP or electrical stimulation. In a phase II clinical trial, olcegepant reduced the severity of headache in 60% of migraine sufferers and met secondary

Store: live-language.pl · Domain: live-language.pl

Description

Smiles: CC1CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]2C=1CC[C@@]2(C)O

CAS Number: 480449-71-6

PF-03716556 is a potent

Smiles: CCOC(=O)C1=CN=CN1[C@H](C)C1C=CC=CC=1

InChi: InChI=1S/C20H21N3O2/c1-12-6-5-7-14(21-12)18-17(22-19(23-18)20(2

Olcegepant - CAS# 204697-65-4 Catalog No.:M10814-10 Smiles: CC1CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]2C=1CC[C@@]2(C)OOlcegepant, also known as BIBN 4096 or BIBN 4096BS is is the first potent and selective non peptide antagonist of the calcitonin gene related peptide 1 (CGRP1) receptor, a key modulator in neurogenic inflammatory pain. In preclinical studies, olcegepant attenuated arterial dilation induced by CGRP or electrical stimulation. In a phase II clinical trial, olcegepant reduced the severity of headache in 60% of migraine sufferers and met secondary

Exchange/Return Notes
  • We offer a 30-day return/exchange service after receiving.
  • Final sale items are not eligible for returns or exchanges.
  • To process your return/exchange, please contact us at [email protected]
  • Please click here for more details>>> Return & Exchange Policy

You may also like

recommand products